Renan Galvão Ozório

Renan Galvão Ozório

Auto-generated profile, based on publicly available information

Renan Galvão Ozório

Universidade Federal do Ceará, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in 3 Biotech
Verified
Journal Article
Open access
PDF file
José Ednésio da Cruz FreireJosé Ednésio da Cruz Freire
José Ednésio da Cruz Freire
JJJosé Edvar Monteiro Júnior
José Edvar Monteiro Júnior
DPDaniel Pascoalino Pinheiro
Daniel Pascoalino Pinheiro
GLGrayce Lima
Grayce Lima
CACamila Lopes Do Amaral
Camila Lopes Do Amaral
Renan Magalhães Montenegro JuniorRenan Magalhães Montenegro Junior
Renan Magalhães Montenegro Junior
The current outbreak of COVID-19 cases worldwide has been responsible for a significant number of deaths, especially in hospitalized patients suffering from comorbidities, such as obesity, diabetes, hypertension. The disease not only has prompted an interest in the pathophysiology, but also it has propelled a massive race to find new anti-SARS-CoV-2 drugs. In this scenario, known drugs commonly used to treat other diseases have been suggested as alternative or complementary therapeutics. Herein we propose the use of sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP4) used to treat type-II diabetes, as an agent to block and inhibit the activity of two proteases, 3CLpro and PLpro, related to the processing of SARS-CoV-2 structural proteins. Inhibition of these proteases may possibly reduce the viral load and infection on the host by hampering the synthesis of new viruses, thus promoting a better outcome. In silico assays consisting in the modeling of the ligand sitagliptin and evaluation of its capacity to interact with 3CLpro and PLpro through the prediction of the ligand bioactivity, molecular docking, overlapping of crystal structures, and molecular dynamic simulations were conducted. The experiments indicate that sitagliptin can interact and bind to both targets. However, this interaction seems to be stronger and more stable to 3CLpro (ΔG = −7.8 kcal mol−1), when compared to PLpro (ΔG = −7.5 kcal mol−1). This study suggests that sitagliptin may be suitable to treat COVID-19 patients, beyond its common use as an anti-diabetic medication. In vivo studies may further support this hypothesis.

1 January 2022 in Acta Ortopedica Brasileira
Verified
Journal Article
Open access
JNJonatas Brito DE Alencar Neto
Jonatas Brito DE Alencar Neto
EOErica Damasceno Oliveira
Erica Damasceno Oliveira
MBMárcio Carvalho Castelo Branco
Márcio Carvalho Castelo Branco
RORenan Galvão Ozório
Renan Galvão Ozório
ASAntônio Anderson Fonseca DE Sousa
Antônio Anderson Fonseca DE Sousa
RLRamille Araújo Lima
Ramille Araújo Lima
Objective: To analyze the epidemiological transition of fractures in patients who were treated in a tertiary hospital which is reference in traumatology during the COVID-19 pandemic to assess the changes in trauma service. Methods: This is a retrospective and descriptive analysis of data on orthopedics lesions treated at Instituto Doutor Jose Frota between December 16, 2019 and June 16, 2020 (three months before and after the first case of COVID-19 in Ceará). Results: In total, we evaluated 913 patients, 28.5% of which were women and 71.5%, men. We found a significative reduction (p < 0.05) in the proportion of female patients operated in the analyzed time. We also observed an increase in patients’ mean age, 35.4 years before the pandemic, and 38.48 (p = 0.04) during the consecutive period. Trauma mechanisms significantly changed (p < 0.05), with a proportional increase of high-energy traumas and reduction of instances of falling. We found a 11.9% reduction in orthopedic surgeries, from 655 to 577 at the time after the first case of COVID-19 (p = 0.071). Mean hospitalization length (p < 0.001) and time until surgeries decreased (p < 0.001). Conclusion: We observed the impact of lockdown in this hospital of trauma especially via the decreased number of operated cases and the change in patients’ profile and trauma mechanism. Level of Evidence III, Retrospective Comparative Study.